dr. wakelee on benefits of osimertinib in egfr-mutant nsclc treatment
Published 5 years ago • 559 plays • Length 1:57Download video MP4
Download video MP3
Similar videos
-
2:03
dr. wakelee on rationale to explore osimertinib with concurrent chemotherapy in egfr-mutant nsclc
-
1:35
dr. herbst on the benefit of adjuvant osimertinib in egfr-mutant nsclc
-
1:05
dr. wakelee on recent advancements in egfr-mutant nsclc
-
1:16
dr. wakelee on first-line therapy for egfr-mutant lung cancer
-
4:04
treating with osimertinib in egfr-mutated nsclc
-
3:02
osimertinib in advanced egfr t790m-mutant nsclc
-
3:27
egfr-mutant nsclc: selecting patients for osimertinib
-
1:27
dr. wakelee discusses egfr tkis in lung cancer
-
1:29
dr. wakelee on available treatments following tumor progression in lung cancer
-
5:52
treatment of egfr nsclc after osimertinib
-
2:19
dr. wakelee on detection of egfr t790m mutation in nsclc
-
58:47
15 years of advances in egfr mutant lung cancer
-
0:50
treating patients with egfr-mutant lung cancer with targeted therapies
-
3:31
osimertinib plus gefitinib for treatment of egfr-mutated non-small cell lung cancer
-
3:30
osimertinib for uncommon egfr mutations in nsclc
-
1:13
dr. wakelee discusses the future of lung cancer adjuvant therapy
-
1:26
dr. wakelee on explaining adjuvant therapy benefits to patients
-
1:23
dr. wakelee discusses current state of treatment in nsclc
-
2:21
osimertinib ipilimumab in egfr-mutated nsclc